Scholarlink

<p>Laser therapy plays an essential role in the management of melasma. However, direct comparisons between the fractional Q-switched ruby laser (fQSRL) and the Q-switched 1064-nm Nd: YAG laser (QSNY) are limited, particularly in Asian populations. Therefore, we conducted this study to compare the clinical efficacy, safety, and patient-reported outcomes of fQSRL versus QSNY in the treatment of melasma.&#xa0;In this randomized, assessor-blinded, split-face study, 21 Chinese women (Fitzpatrick skin types III–IV) with bilateral melasma received 3 to 6 treatment sessions with fQSRL and QSNY, administered at three-week intervals. Efficacy, safety, and patient satisfaction were assessed.&#xa0;Both lasers achieved a 62.0% response rate, with no significant difference in hemi-mMASI score reduction (<i>P</i> &gt; 0.05). Patient satisfaction scores were similar between treatments. However, pain scores were significantly higher with fQSRL than with QSNY (<i>P</i> &lt; 0.0001). Post-inflammatory hyperpigmentation occurred bilaterally in one patient (4.8%), with no serious adverse events reported.&#xa0;QSNY and fQSRL demonstrated comparable efficacy in treating melasma in Chinese women. However, the higher pain associated with fQSRL may limit its patient acceptability. Further large-scale, multicenter studies are needed to confirm long-term efficacy and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A pilot randomized split-face trial comparing fractional Q-Switched ruby laser and 1064-nm Q-Switched nd: YAG laser in Chinese women with melasma running titile: fQSRL vs. QSNY in melasma

  • 期刊论文

  • 发表日期：

    2025年10月4日

查看全文
  • Yumei Gao,
  • Yalan Bi,
  • Eray Yihui Zhou,
  • Zhenghui Li,
  • Jie Ren,
  • Yi Zhao

摘要

Laser therapy plays an essential role in the management of melasma. However, direct comparisons between the fractional Q-switched ruby laser (fQSRL) and the Q-switched 1064-nm Nd: YAG laser (QSNY) are limited, particularly in Asian populations. Therefore, we conducted this study to compare the clinical efficacy, safety, and patient-reported outcomes of fQSRL versus QSNY in the treatment of melasma. In this randomized, assessor-blinded, split-face study, 21 Chinese women (Fitzpatrick skin types III–IV) with bilateral melasma received 3 to 6 treatment sessions with fQSRL and QSNY, administered at three-week intervals. Efficacy, safety, and patient satisfaction were assessed. Both lasers achieved a 62.0% response rate, with no significant difference in hemi-mMASI score reduction (P > 0.05). Patient satisfaction scores were similar between treatments. However, pain scores were significantly higher with fQSRL than with QSNY (P < 0.0001). Post-inflammatory hyperpigmentation occurred bilaterally in one patient (4.8%), with no serious adverse events reported. QSNY and fQSRL demonstrated comparable efficacy in treating melasma in Chinese women. However, the higher pain associated with fQSRL may limit its patient acceptability. Further large-scale, multicenter studies are needed to confirm long-term efficacy and safety.